Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(10 sites) United States
UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research, La Jolla, California University of California San Francisco, San Francisco, California Emory University, Atlanta, Georgia Brigham and Women's Hospital, Boston, Massachusetts Mayo Clinic, Rochester, Minnesota The Christ Hospital Physicians - The Ohio Heart and Vascular Center, Cincinnati, Ohio Cleveland Clinic, Cleveland, Ohio Oregon Health & Science University, Portland, Oregon Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania Houston Methodist Hospital, Houston, Texas